After a median of 2 years, 92% of advanced kidney cancer patients pretreated with immunotherapy show objective response or stable disease on novel combination therapy, according to interim results from phase 2 trial led by Toni K, Choueiri, MD of Dana-Farber Cancer Institute. Study reported in The Lancet Oncology. Video posted April 3, 2023.
